Cover Image
市場調查報告書

C型肝炎:競爭情形,市場分析,開發平台分析

Hepatitis C - Competitive Landscape, Market and Pipeline Analysis 2017

出版商 DelveInsight Business Research LLP 商品編碼 546077
出版日期 內容資訊 英文 234 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
C型肝炎:競爭情形,市場分析,開發平台分析 Hepatitis C - Competitive Landscape, Market and Pipeline Analysis 2017
出版日期: 2017年11月01日 內容資訊: 英文 234 Pages
簡介

本報告提供C型肝炎治療藥的相關調查,市場概要,各臨床實驗階段的產品概要,關於已上市、開發暫停中的產品的評估,市場促進因素及課題分析等總括性彙整。

目錄

  • 摘要整理
  • 概要
  • 已上市醫藥品
  • 臨床實驗中的產品:第三階段實驗
  • 臨床實驗中的產品:第二階段實驗
  • 臨床實驗中的產品:第一階段實驗
  • 臨床試驗前中的產品
  • 治療藥的評估:已上市的產品
  • 治療藥的評估:開發暫停中的產品
  • 市場的推動要素與課題
  • 附錄

圖表清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DISR0014

DelveInsight's, "Hepatitis C - Competitive Landscape, Market and Pipeline Analysis 2017", report provides comprehensive insights about different therapeutic drugs for the treatment of Hepatitis C. A key objective of the report is to provide market and competitive landscape; and pipeline products for Hepatitis C.

The report provides in-depth details of 20+ marketed products, which are currently leading the market. It also provides the therapeutic details of the marketed product in this area, along with their historical and forecasted sales till 2022. It also covers the 15+ companies, which are active in this field with 30+ therapeutic pipeline drugs that are currently under development for the treatment of Hepatitis C including their comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, Pre-clinical and Discovery stage products. Additionally, Forecasted sales of Phase III drugs are also incorporated in the report. A separate section for inactive products is also included in the report.

Comparative analysis of therapeutic drugs at various stages and their therapeutic assessment by product type and molecule type provides additional and vital details of the pipeline drugs. The report also provides the market drivers and barriers for Hepatitis C drugs for the enhanced pipeline of Hepatitis C. Information on various technologies involved in the development of pipeline therapeutics along with all the collaborations and agreements of the respective company brings added the advantage of this report. Patent and Financing details related to the products are also provided.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Table of Contents

  • Executive Summary
  • Overview
  • Marketed Drugs
  • Pipeline Therapeutics
  • Last Stage Products (Filed and Phase III)
  • Mid Stage Products (Phase II)
  • Early Stage Products (Phase I)
  • Pre-clinical and Discovery Stage Products
  • Therapeutic Assessment: Active Products
  • Inactive Products
  • Market Drivers and Barriers
  • Appendix

List of Tables

  • Table 1: Total Products for Hepatitis C
  • Table 2: Late Stage Products (Filed and Phase III)
  • Table 3: Mid Stage Products (Phase II)
  • Table 4: Early Stage Products (Phase I)
  • Table 5: Pre-clinical and Discovery Products
  • Table 6: Assessment by Monotherapy Products
  • Table 7: Assessment by Combination Therapy Products
  • Table 8: Assessment by Route of Administration
  • Table 9: Assessment by Stage and Route of Administration
  • Table 10: Assessment by Stage and Molecule Type
  • Table 11: List of Dormant Products
  • Table 12: List of Discontinued Products

List of Figures

  • Figure 1: Course of Illness with Hepatitis C
  • Figure 2: Global Epidemiology of Hepatitis C
  • Figure 3: HCV Life Cycle and Pathogenesis
  • Figure 4: Total Products for Hepatitis C
  • Figure 5: Late Stage Products (Filed and Phase III)
  • Figure 6: Mid Stage Products (Phase II)
  • Figure 7: Early Stage Products (Phase I)
  • Figure 8: Pre-clinical and Discovery Products
  • Figure 9: Assessment by Monotherapy Products
  • Figure 10: Assessment by Combination Therapy Products
  • Figure 11: Assessment by Route of Administration
  • Figure 12: Assessment by Stage and Route of Administration
  • Figure 13: Assessment by Stage and Molecule Type
  • Figure 14: Dormant Products
  • Figure 15: Discontinued Products
Back to Top